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was based on the average monthly salary in the UK. A conservative assumption was 
made about the increased risk of a productive day being lost – associated with level 
of patient satisfaction to their treatment – by calculating an approximate number of 
unscheduled hospitalisations that users of a new inhaler would experience in the 
previous 12 months relative to Spiriva® HandiHaler®. Patient satisfaction with their 
inhaler was based on inhaler features that relate to ease of use and ergonomics and 
compared Spiriva® HandiHaler® to an improved inhaler. Results: The frequency 
of unscheduled hospitalisations for the new inhaler and Spiriva® HandiHaler® users 
were calculated at 0.34 and 0.38, resulting in 68 and 76 productive days lost annually, 
respectively. The total annual societal cost per patient was € 9,851 with the new inhaler 
and € 10,891 with Spiriva® HandiHaler®. The new inhaler costs € 1,040 less per annum 
than Spiriva® Handihaler®. ConClusions: New inhalers with improved features 
have the potential to offer substantial societal cost savings in COPD compared with 
Spiriva® Handihaler®.
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objeCtives: A real-life cost-effectiveness evaluation in 2008 showed that medica-
tion costs of budesonide/formoterol for maintenance and reliever therapy (MART) 
via dry powder inhaler (DPI) was significantly lower than medication costs associ-
ated with fixed-dose combination (FDC) of budesonide/formoterol in conventional 
way (FDC of ICS/LABA + additional reliever) and free adjustable combination (FAC) 
of budesonide and formoterol, with at least equal effectiveness. In 2014 the Dental 
and Pharmaceutical Benefits Agency (TLV) in Sweden assessed all inhaled corticos-
teroids (ICS), long-acting beta-2-agonists (LABA) and their FDCs where the outcomes 
suggested equal effectiveness across treatment strategies and a pricing corridor was 
implemented. The objective is to update the medication costs for a real-life cost-
effectiveness analysis of treating asthma in Swedish primary care and to evaluate 
the medication costs in Denmark. Methods: Medication costs from 2006 included 
all pharmaceuticals in the analysis which were inflated to 2015 price levels and then 
compared to today’s actual prices of medications used in the FAC arm (Pulmicort® 
Turbuhaler® & Oxis® Turbuhaler®, plus terbutaline as needed), FDC arm (Bufomix® 
Easyhaler® plus terbutaline as needed) and the budesonide/formoterol MART arm 
(DuoResp® Spiromax®). The same analysis was conducted for both Sweden and 
Denmark. Results: The medication costs in the budesonide/formoterol MART arm 
is less costly when considering DuoResp® Spiromax®, SEK 3336.4 (SEK 4710.9) per 
patient and year compared to SEK 4163 (SEK 6157) in the FDC arm and SEK 7498.5 
(SEK 5637.6) FAC arm. In Denmark the same trend is visible where the MART arm 
was DK 4183.5 (DK 4573) compared to DK 4579 (DK 5905.2) in the conventional FDC 
arm and 4510.4 (DK 4511.7) in the FAC arm. ConClusions: Compared to conven-
tional treatment arm (FDC + reliever) and free adjustable combination (FAC) arm, 
DuoResp® Spiromax® with MART usage has the potential to be cost saving option 
with at least equivalent efficacy.
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objeCtives: This study aimed at estimating the cost-effectiveness of the fixed-dose 
combination indacaterol/glycopyrronium 85/43μ g (IND/GLY) against tiotropium 18μ g 
(TIO) and salmeterol/ fluticasone 50/500μ g (SFC) in the management of patients with 
COPD in Greece. Methods: A microsimulation model was developed in MS Excel. 
Efficacy and utility data were obtained from the international literature (SHINE & 
ILLUMINATE studies) and mortality data from the WHO database. Distribution of 
patients by GOLD severity stage, maintenance costs and costs associated with severe/ 
non-severe exacerbations were taken from published Greek studies. Unit costs were 
taken from officially published sources (Price Bulletin, reimbursement list, DRGs). The 
study perspective was that of the Social Insurance Fund; costs and outcomes were 
discounted at 3.5%; outcomes are reported over time horizons of one, three, five and 
10 years and over a lifetime. Cost base year was 2014. Deterministic and probabilistic 
sensitivity analyses were conducted to test robustness of model results. Results: 
Treatment of COPD with IND/GLY is associated with increased efficacy both against 
SFC (additional life years [LYs]: 0.19; additional quality adjusted life-years [QALYs]: 
0.13) and TIO (additional LYs: 0.22; QALYs: 0.16). Although IND/GLY has a higher 
pharmaceutical cost (additional € 2,626 vs. SFC; additional € 2,679 vs. TIO), all other 
cost components (maintenance costs, severe and non-severe exacerbation costs) 
are reduced, resulting in a reduction of total costs by € 5,204 compared with SCF 
and € 7,126 compared with TIO. The sensitivity analyses confirmed that IND/GLY 
was dominant in the majority of iterations, with a probability of being cost effective 
at a threshold of € 30,000 per QALY gained of 99.9% and 97.1% versus SFC and TIO, 
respectively. ConClusions: IND/GLY was found to be a dominant treatment strategy 
compared to SFC and TIO for the management of patients with COPD in Greece, which 
could lead to savings for the healthcare system.
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(r = 0.09 with Spearman and Pearson tests). ConClusions: There is a decrease in 
the COPD hospitalizations after the introduction of the new inhaled medicines and 
increase in their cost due to increase in the cost of services.
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objeCtives: Long-acting β 2-agonists (LABAs) and long-acting muscarinic antago-
nists (LAMAs) have shown efficacy in preventing exacerbations in patients with 
COPD. Though these agents are effective in the treatment of COPD, deterioration 
in the patient health status can persist and therefore there is a need for improved 
treatment outcomes. In the SPARK trial, dual bronchodilation with QVA149 demon-
strated advantages in reducing the risk of COPD exacerbations in severe and very 
severe patients when compared to single bronchodilation with tiotropium. The 
objective of the study was to stimate the clinical benefits and the budget impact 
associated with the use of indacaterol 110 μ g/glycopyrronium 50 μ g (QVA149) instead 
of tiotropium 18 μ , in severe and very severe COPD patients (GOLD C and D) in 
Portugal. Methods: A cost-consequence model was developed using the SPARK 
study data to derive treatment outcomes associated to the use of QVA149 instead 
of tiotropium. Primary outcomes of interest were COPD exacerbations and direct 
cost for the NHS. Treatment outcomes and costs were estimated for a 1 year. Local 
data was used to identify the target population, resource use and overall treat-
ment costs. Results: It is estimated that there are 11,239 GOLD C and D patients 
treated with tiotropium. Assuming that 20.5% of COPD patients see their primary 
care doctor with complaints about symptoms and exacerbations 2,304 of those 
patients could be treated instead with QVA149. After 1 year of treatment with QVA 
149 it is estimated that patients will experience 1,291 fewer exacerbations with a 
reduction of € 136,544 in the overall treatment costs compared to treatment with 
tiotropium. ConClusions: Symptom control in COPD is essential and evidence 
shows that dual bronchodilation with QVA149 brings benefits when compared to 
tiotropium. The use of QVA149 in symptomatic patients instead tiotropium may 
improve treatment outcomes and reduce overall costs for the Portuguese NHS.
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objeCtives: In the LANTERN study QVA149 significantly reduced the rate of mod-
erate or severe exacerbations by 31% (p= 0.048) over Salmeterol/Fluticasone (SFC). 
The evidence suggests that the use of QVA149 can optimize treatment outcomes 
in patients with mild-to-severe COPD but at what cost to the Portuguese NHS? 
The study objective was to quantify the potential clinical benefits and the budget 
impact associated with the use of QVA149 and SFC in the treatment of Portuguese 
patients with moderate-to-severe COPD with few or no exacerbations. Methods: 
A cost-consequence model was developed using the LANTERN study data to derive 
treatment outcomes for QVA149 and SFC. Primary outcomes of interest were COPD 
exacerbations (total, moderate and severe) and direct cost for the Portuguese NHS. 
Treatment outcomes and costs were estimated for 1 year time horizon. Local data 
was used to identify the target population, resource uses and overall treatment 
costs. Results: It is estimated that there are 73,739 GOLD B patients diagnosed 
and treated in Portugal and 34,778 of those patients are treated with SFC and could 
be eligible to receive treatment with QVA149. After one year of treatment with SFC 
it is estimated that these patients may experience 30,605 exacerbations (15,650 
moderate/severe) with a total treatment cost of € 69,268,710. If treated with QVA149 
it is estimated that these patients may experience 6,608 fewer exacerbations (4,869 
fewer moderate/severe) with a total treatment cost saving of € 8,524,307 versus SFC 
treatment. ConClusions: The analysis suggest that once a day QVA149 can pro-
vide better treatment outcomes in patients with COPD with fewer treatment costs 
for the Portuguese NHS when compared with twice a day SFC in the treatment of 
moderate-to-severe COPD with few or no exacerbations.
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objeCtives: Spiriva® Handihaler® (tiotropium) is available in a single capsule 
dry powder inhaler (DPI) for the treatment of COPD. As exacerbations and hospi-
talisations represent an important driver of the cost and morbidity of COPD, high 
priority should be given to interventions aimed at delaying the progression of dis-
ease, preventing exacerbations, and reducing the risk of comorbidities to alleviate 
the clinical and economic burden of disease. The potential societal cost benefits of 
improving treatment satisfaction, due to improved characteristics of an inhaler were 
investigated. Methods: The eligible adult patient population was based on con-
firmed COPD diagnoses in UK, with the proportion of patients receiving Spiriva® 
Handihaler® based on market research data. The annual number of work days lost 
due to COPD was based on data from the UK. The monetary value of a productive day 
